drugset / Trial / NCT07047755
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, phase II study evaluating the efficacy and safety of Trastuzumab Rezetecan in combination with pertuzumab in early or locally advanced HER2-positive breast cancer.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-07-01
- Completion
- 2031-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |